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N-end ruleThe human APOBEC3G (A3G) is a potent inhibitor of HIV-1 replication and its activity is suppressed by HIV-1
virion infectivity factor (Vif). Vif neutralizes A3G mainly by inducing its degradation in the proteasome and
blocking its incorporation into HIV-1 virions. Assessing the time needed for A3G incorporation into virions is,
therefore, important to determine how quickly Vif must act to induce its degradation. We show that
modelling the intracellular half-life of A3G can induce its Vif-independent targeting to the ubiquitin–
proteasome system. By using various amino acids (X) in a cleavable ubiquitin-X-A3G fusion, we demonstrate
that the half-life (t1/2) of X-A3G can be manipulated. We show that A3G molecules with a half-life of 13 min
are incorporated into virions, whereas those with a half-life shorter than 5 min were not. The amount of X-
A3G incorporated into virions increases from 13 min (Phe-A3G) to 85 min (Asn-A3G) and remains constant
after this time period. Interestingly, despite the presence of similar levels of Arg-A3G (t1/2=28 min) and
Asp-A3G (t1/2=65 min) into HIV-1 Δvif virions, inhibition of viral infectivity was only evident in the
presence of A3G proteins with a longer half-life (t1/2≥65 min).
© 2009 Elsevier Inc. All rights reserved.Introduction
The human apolipoprotein B mRNA-editing enzyme, APOBEC3G
(A3G), is a potent host antiretroviral enzyme that can restrict HIV-1
infection by two known mechanisms. First, A3G is incorporated into
HIV-1 virions during viral production and subsequently induces hyper-
mutation of viral cDNA through cytidine deamination of newly synthe-
sized reverse transcripts (Mariani et al., 2003; Soros et al., 2007; Stopak
et al., 2003; Suspene et al., 2004; Yu et al., 2004a; Xu et al., 2007). This
mode of action is counteracted by HIV-1 Vif that prevents incorporation
of A3G into virions. The viral protein acts predominantly by forming a
Cul5-E3 ubiquitin ligase complex that target these proteins for degra-
dation by the ubiquitin–proteasome pathway (Conticello et al., 2003;
Liu et al., 2005;Marin et al., 2003; Mehle et al., 2004a, 2004b; Sheehy et
al., 2003; Stopak et al., 2003; Yu et al., 2004b, 2003). Second, cellularA3G
can function as a potent post-entry restriction factor for HIV-1 during
reverse transcription in resting CD4+ T cells (Chiu et al., 2005).
It was recently proposed that polyubiquitinated Vif could function
as a vehicle to transport A3G for proteasome degradation (Dang et al.,lecular, Faculdade de Farmácia
1649-059, Portugal. Fax: +351
).
ll rights reserved.2008). It has been shown that Vif is polyubiquitinated and subject to
proteasome degradation without A3G (Akari et al., 2004; Mehle et al.,
2004a), and this reaction is catalyzed by the same Cul5-E3 ligase
complex (Mehle et al., 2004b). Thus, the mechanism by which Vif
destabilizes A3G and mediates its degradation is still under debate.
Cellular proteases mediate protein degradation, which vary from
small proteins such as extracellular trypsin and intracellular caspases,
to large, ATP-dependent proteases that mediate the destruction of
ubiquitin-protein conjugates called the 26S proteasome (Baumeister
et al., 1998).
Intracellular protein degradation involves ubiquitin conjugation
(Ciechanover et al., 1978; Hershko et al., 1980, 1983) and the selec-
tivity of this conjugation is determined by speciﬁc degradation signals
(degrons) in short-lived proteins (Bachmair et al., 1986; Bachmair
and Varshavsky, 1989; Chau et al., 1989; Johnson et al., 1990; Bartel et
al., 1990). Ubiquitin-dependent processes play a major role in cellular
physiology (Finley et al., 1984; Jentsch et al., 1987; Finley et al., 1987;
Goebl et al., 1988; Finley et al., 1989; Hochstrasser and Varshavsky,
1990; Hochstrasser et al., 1991), primarily by controlling the levels of
intracellular protein.
Metabolic instability of short-lived proteins allows for efﬁcient
temporal control of their intracellular concentrations and was shown
to be essential for the regulatory functions of several eukaryotic and
bacterial proteins (Nasmyth, 1983; Banuett et al., 1986; Bahl et al.,
Fig. 1. Schematic representation of A3G bicistronic expression vector (pEGFP⁎IRES-Ub-X-
A3G-HA). Transcription of the mRNA is initiated at the cytomegalovirus promoter/
enhancer upstream of the EGFP coding sequence. The translation start and stop codon for
EGFP and Ub-X-A3G is shown. The site for the post-translational cleavage between Ub and
X-A3G is shown with a downward arrow. EGFP protein was used with a standardization
purpose asan internal control for the synthesis of the EGFP-IRES-Ub-X-A3G transcript. This
was achieved by the presence of an internal ribosomal entry site (IRES), which allows the
creation of a bicistronic transcription unit, inwhich EGFP and Ub-X-A3G sequenceswill be
translated independently. The amino acid residues used in this study are indicated, which
in eukaryotes are classiﬁed as stabilizing and destabilizing, according to the half-life that
they confer to the protein (Varshavsky, 1996).
Fig. 2. Expression of A3G mutants. (A) Wild-type A3G and N-terminal A3G mutants are
shown above asWT,Met, Gly, Asn, Asp, Arg, Phe, and Leu. EGFP expression is shown as a
control for the transfection. GAPDH is shown as a general control to the quantity of
protein loading in Western blotting. Brieﬂy, 2 μg of each plasmid was used to transfect
293T cells in 6-well plates. 40–44 h after transfection cells were washed twice with
room-temperature PBS and lysed in cold RIPA lysis buffer. Lysates were subjected toWB
analysis. (B) The stability of A3Gvariants is regulated by theproteasome. 293T cellswere
transfected with equal amounts of Ub-Arg-A3G, Ub-Phe-A3G and Ub-Leu-A3G isogenic
plasmids. 36 h after transfection, cells were treated with proteasome inhibitor MG-132
(20 μM) for 4 h and analyzed by SDS-PAGE after lysis. The blots were probed with anti-
HA antibody, stripped, and reprobed with anti-EGFP or anti-GAPDH antibody. The
intensity of Arg-A3G, Phe-A3G and Leu-A3G bands increases with proteasome inhibitor
MG132 showing that degradation of these proteins will not occur. These results conﬁrm
that Arg-A3G, Phe-A3G and Leu-A3G are expressed but with low steady-state.
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macromolecular complexes such as ribosomes and oligomeric pro-
teins are metabolically unstable in a free, unassociated state (Maicas
et al., 1988; Tsay et al., 1988).
In this study, we decided to manipulate the cytoplasmic half-life of
A3G protein to allow for an efﬁcient control of its intracellular
concentration. By doing this, we sought to understand how A3G half-
life can inﬂuence its antiviral activity independently of Vif. To achieve
this aim, we have adapted the ubiquitin-fusion technique, ﬁrst
described by Varshavsky et al. (Bachmair et al., 1986). This strategy
relates the intracellular half-life of a protein to the identity of its N-
terminal residue. This method involves the fusion of an ubiquitin
monomeric moiety immediately adjacent to the N-terminal amino acid
of a protein, which here results in an ubiquitin-A3G fusion protein.
Fusions to Ub are co-translationally cleaved at the Ub-protein junction
by speciﬁc proteases. This approach allowed replacing the ﬁrst amino
acid sequence of A3G (ATG) by any desired amino acid described by the
N-end rule (Baker 1996; Varshavsky 1996). The set of individual amino
acids introduced at theN-terminusofA3Ghas beenpreviously classiﬁed
according to the half-life they confer to the protein (Bachmair et al.,
1986; Bachmair and Varshavsky, 1989; Gonda et al., 1989; Kwon et al.,
1998; Tasaki et al., 2005; Varshavsky, 1996). They encompass four
classes of amino acids in the N-end rule: primary (Leu, Phe, and Arg),
secondary (Asp), tertiary (Asn), and stabilizing (Met and Gly) residues.
Primary residues are the least stables aminoacids (Varshavsky, 1996). In
this study, wt A3G maintains Met at its N-terminus.
Using this strategy we were able to destabilize the intracellular
A3G molecules, mimicking the effect of Vif on A3G steady-state. This
approach allowedmonitoring the intracellular activity of A3G in a Vif-
free environment. By reducing the half-life of each A3G protein we
showed that incorporation into viral particles occurs shortly after A3G
synthesis (t1/2=13 min). Interestingly, similar levels of Arg-A3G
(t1/2=28 min) and Asp (t1/2=65 min) were detected into HIV-1
virions. However, inhibition of viral infectivity is only detected in the
presence of A3G proteins with a longer half-life (t1/2≥65 min).
Results
Modulation of APOBEC3G half-life by the N-end rule pathway
We sought to manipulate the half-life of A3G to assess whether the
quantity of protein correlates with viral incorporation and antiviralinfectivity. With this goal in mind, we expressed A3G proteins with a
dissimilar intracellular half-life. Mechanistically, the system is based
on deubiquitylating enzymes that potently and rapidly cleave the
junction between the C-terminus of ubiquitin and the N-terminus of a
fused protein domain, in a process called deubiquitination. Thus,
we fused the coding sequence for humanUbwith A3G to generate Ub-
X-A3G, where X represents any class of amino acids described by the
N-end rule. According to the identity of the amino acid used at N-
terminus, this arrangement allowed us to obtain A3G variants with
different half-lives. In this study, we used a panel of seven different
amino acids that have been described as involved in the N-end rule
pathway (Bachmair et al., 1986; Gonda et al., 1989; Varshavsky,
1996). The schematic representation of the EGFP-IRES-Ub-X-A3G
fusion construct and the amino acids used at the N-terminus of A3G is
represented in Fig. 1.
Vif has been proposed to target A3G for accelerated degradation
in the 26S proteasome via the ubiquitin–proteasome pathway
(Conticello et al., 2003; Liu et al., 2005; Marin et al., 2003; Mehle
et al., 2004a, 2004b; Sheehy et al., 2003; Stopak et al., 2003; Yu et al.,
2004b, 2003). A similar situation occurs with the N-end rule
substrates that are bound by a targeting complex, followed by for-
mation of a substrate-linked multi-Ub chain. The ubiquitylated sub-
strate is processively degraded by the 26S proteasome. To determine
whether Ub-X-A3G follows the 26S proteasome degradation pathway
Fig. 3. Cycloheximide chase analysis. A3GWT and N-terminal A3G variants were expressed in 293T cells (60-mm plates) and, the second day after transfection the cells were split in
6-well plates and the translation inhibitor cycloheximide (100 μg/ml) was added to each of the cell cultures. 293T cells expressing A3GWT, Met-A3G, and Gly-A3G were incubated
with cycloheximide for 1, 2, 3, and 4 h; for Asn-A3G and Asp-A3G expression were incubated 1, 2, and 3 h; for Arg-A3G and Phe-A3G expression were incubated 20, 40, and 60 min,
and 5, 10, and 20 min for Leu-A3G. The zero time-point received drug-free diluent DMSO. Cellular lysates were obtained at each time-point and the protein content was analyzed by
WB using the anti-HA HRP-conjugated monoclonal antibody (Roche). α-GAPDH antibody was used as a loading control. Above each western-blot, the mean relative value of band
density (INT/mm2) from three independent experiments was plotted against time. A linear regression line was drawn through the data points and was used to calculate the half-life
value of each protein, which is shown between brackets.
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A3G sequence by six different residues.
Methionine at the N-terminus of A3G sequence was used as a
control for expression of wild-type deaminase in this system. The
corresponding recombinant plasmids EGFP-IRES-Ub-X-A3G are iso-
genic except for the sequence of the ﬁrst amino acid of A3G. To
determine the half-life of the different A3G constructs we transfected
equal amounts of different Ub-X-A3G plasmids in 293T cells. The
expression proﬁles obtained for the different A3G variants showed
that the proteins containing stable residues (Met and Gly), tertiary
residue (Asn) and secondary residue (Asp) have higher expression
levels than those having the least stable residues (Arg, Phe and Leu)
(Fig. 2A). This vector was designed to have the coding sequence of the
EGFP under the control of the cytomegalovirus promoter, along with
an internal ribosomal entry site (IRES) upstream of the Ub-X-A3G
sequence. This arrangement allows expression of EGFP independently
of A3G. Therefore, while A3G expression should be different according
to amino acid present at the N-terminus, EGFP levels should remain
similar for all the constructs allowing us to monitor the efﬁciency of
DNA transfection.
As seen in Fig. 2A, the molecular weight of different X-A3G pro-
teins was similar to the wild-type deaminase showing that ubiquitin
(Ub) was cleaved off fromA3G. In addition, GAPDH control shows that
these differences regarding Ub-X-A3G expression were not due to
protein loading. To discard a possible toxicity effect due to the
chimeric A3G expression, a cell viability assay was performed using
the tetrazolium salt WST-1 (Roche), which showed that the diffe-
rences observed were not due to abnormal cell physiology (data not
shown).
The half-life of the least stable proteins (Arg-A3G, Phe-A3G and
Leu-A3G) was signiﬁcantly higher when the transfected cell cultures
were treated with proteasome inhibitor, MG132. With this inhibitor
the steady-state of X-A3G proteins increase and the corresponding
bands appear stronger in the western-blot. As shown in Fig. 2B, Arg-
A3G, Phe-A3G, and Leu-A3G proteins were barely evident without
inhibitor. These results show that our A3G constructs are physiolo-
gical substrates of the ubiquitin–proteasome degradation pathway,
and the lower level of expression detected for Arg-A3G, Phe-A3G and
Leu-A3G was indeed a consequence of the amino-terminal destabili-
zing residue.
Kinetics of the in vivo degradation of A3G variants
The observation that A3G is incorporated into the virion core sug-
gests several sources of the deaminase. Most likely, the mechanism of
A3G virion incorporation depends on the amount of deaminase present
in the cytoplasm capable to be targeted into the virion. One important
variable for this mechanism is the required time for its recruitment into
the virion core. It is conceivable that A3G cannot be readily rescued for
virion incorporation when it is bound to the cellular high molecular
mass (HMM) complex. Therefore, ﬁne-tuning A3Ghalf-lives can help toFig. 4. Detection of X-A3G proteins in the presence of Vif. 293T cells were cotransfected in a
1 μg of pcDNA-Vif. 40–44 h after transfection, cells were lysed and protein content was anaunderstand the time–space relationship of A3G targeting to the viral
particle. The N-end rule should then provide an efﬁcient temporal
control of A3G intracellular concentration.
To assess whether the different A3G constructs could be used with
this intention, we carried out a cycloheximide chase analysis to
monitor the in vivo decay of A3G proteins. We used this approach,
instead of pulse–chase analysis, because we aimed to monitor the
turnover of existing proteins and to examine newly synthesized
molecules. In addition, due to the expected rapid degradation of our
least stable proteins, those proteins could only be detected by this
method if the pulse-labeling and chase-times were very short (less
than 5 min).
By treating cells with cycloheximide we showed that the in vivo
half-life of the different A3G proteins varied from less than 5 min to
more than 4 h, depending on the nature of the amino acid residue
present at the amino-terminus of A3G (Fig. 3). Speciﬁcally, deubiqui-
tinated A3G proteins with either Met or Gly at the amino-terminus
displayed a relatively long half-life of more than 4 h, similar to the half-
life of control A3G WT. In contrast, A3G variants bearing N-terminal
destabilizing residues classiﬁed as primary amino acids exhibited very
short half-lives. Cycloheximide chase analysis showed that the half-life
of Arg-A3Gwas about 28min, b20min for Phe-A3G and less than 5min
for Leu-A3G. In addition, the half-life of A3G proteins bearing amino-
terminal residues Asn and Asp was approximately 85 min and 65 min,
respectively.
Amino-terminal A3G variants are targeted to degradation by HIV-1
Vif protein
Due to the mechanism of the N-end rule, it was conceivable that
X-A3G variants could somehow escape the action of Vif by a different
pathway of degradation. It could result that the alteration of the ﬁrst
N-terminal residue in A3G may have affected its subcellular distri-
bution allowing the protein to escape the action of Vif. In this way,
and according to the fact that wild-type A3G stability is impaired in
the presence of Vif protein (Marin et al., 2003; Sheehy et al., 2003;
Stopak et al., 2003; Yu et al., 2003), we sought to determine if our
A3G constructs were targeted for degradation by Vif in a similar
manner. Basing on the expression proﬁles obtained for the different
proteins, those with a longer half-life (Met-A3G, Gly-A3G, Asn-A3G,
and Asp-A3G) were expressed in 293T cells in the presence of Vif
(Fig. 4).
Although all A3G variants were degraded in the proteasome in a
Vif-independent manner, the results obtained showed that they were
also targeted by Vif (Fig. 4). Even with a lower half-life, protein
quantity of the three least stable constructs (Arg-A3G, Phe-A3G, and
Leu-A3G) was also reduced by Vif (data not shown) showing that Vif
binds A3G shortly after its synthesis. These results also show that Ub-
X-A3G fusions and its cleavage products do not have deleterious
affects on deaminase folding, being capable of targeted degradation by
Vif. Moreover, in an in vitro deamination assay all A3G constructs6-well plate with 1 μg of Ub-Met-A3G, Ub-Gly-A3G, Ub-Asn-A3G, and Ub-Asp-A3G, and
lyzed by SDS-PAGE.
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ring a target sequence for A3G deamination, showing that A3G
fusions to Ub did not affect the catalytic activity of the differentFig. 5. Virion incorporation of A3G and viral infectivity. HIV-1 virions were produced by co-tra
A3G plasmids in the presence of 3 μg of pNL4.3Δvif (A) or pNL4.3 (B). 40–44 h after transfec
Materials and methods section. A3G WT was used as a control for infection inhibition. Relati
The remaining virus stocks (1.9 ml) were used for detection of A3G into Δvif virions. Intra
(Roche). (D) Relative A3G virion incorporation was calculated by the ratio of virus- to cell-as
relative values of four independent experiments. (N=4, ⁎pN0.05), (N=4, §pb0.05), (N=4
293T cells in 6-well plates with 0.1, 0.2, 0.5, and 1 μg of wild-type A3G or Phe-A3G, in the pre
A3G into virions was carried in the same conditions as described above. Relative infectivity
(0.1 μg) was used in all transfections to generate VSV-G-pseudotyped virions. DNA amounts
A3G WT transfected in different quantities with pNL4.3Δvif, together with respective pu
expression and virion incorporation of Phe-A3G and A3G WT by western-blot. The westernvariants (Supplementary data). Nevertheless, caution should be taken
when interpreting these results since deamination assays were non-
quantitative.nsfection of 293T cells in 6-well plates, with equal amounts (1 μg) of A3GWT and Ub-X-
tion, virions were collected (100 μl) and used to infect HeLa P4 cells, as described in the
ve infectivity values presented here are the result of four independent experiments. (C)
virion A3G content was detected using anti-HA HRP-conjugated monoclonal antibody
sociated A3Gmeasured by band densitometry. The values obtained, represent the mean
, ⁎⁎pN0.05), (N=4, ξpb0.05). (E) HIVΔvif virions were produced by co-transfection of
sence of 3 μg of pNL4.3Δvif. Infection of HeLa P4 cells and detection of A3GWT and Phe-
values presented here are the result of four independent experiments. VSV-G plasmid
were adjusted to 5 μg using empty pcDNA3.1 vector DNA. Cells lysates of Phe-A3G and
riﬁed virions were run on the same gel to compare relative quantity of intracellular
-blot data represents three independent experiments.
Fig. 6. Quantiﬁcation of A3G transcripts by real-time PCR. A3G, and Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA levels were quantiﬁed by real-time PCR
using SYBR Green (Invitrogen) and according to the manufacturer's instructions. The
ratio of A3G transcripts as normalized to GAPDH is shown. Total RNA was extracted
from 293T cells transfected with A3G in the presence of pNL4.3Δvif. cDNA products
were analyzed by real-time PCR using speciﬁc primers. Quantiﬁcation of A3G trans-
cripts was performed after normalization to GAPDH transcripts. Quantiﬁcation of
mRNA levels showed that these variations observed were not signiﬁcant (pN0.05).
(A3G SD=0.928, GAPDH SD=1.201).
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In this study we sought to investigate how A3G half-life can
inﬂuence its antiviral activity. We ﬁrst asked whether the least stable
A3G proteins were able to inhibit HIV-1 infection without Vif. Viral
stocks were produced by transfection of pNL4.3Δvif into 293T cells,
with equal amounts of A3G WT or N-terminal A3G variants. We also
transfected A3G in the presence of pNL4.3WT plasmid to compare the
infectivity of viruses produced in the presence of Vif. Two days after
transfection, virions were harvested and, after normalization for p24
concentration, were used to infect HeLa P4 cells (Figs. 5A, B). The
remaining HIV-1Δvif viral stock was used for the detection of A3G into
virions (Fig. 5C). Analysis HIV-1Δvif virions revealed the presence of
A3G (Phe-A3G) 13 min after its synthesis (Fig. 5C, lane 7). In contrast,
A3Gwith a half-life of 5min (Leu-A3G)was absent from all the virions
analyzed (Fig. 5C, lane 8). As seen in Fig. 5D, the amount of A3G
incorporated into virions increases from 13 (Phe-A3G) to 85 min
(Asn-A3G), remaining relatively constant after this period of time.
In regard to this observation, we hypothesized that viral infectivity
could be reduced similarly. This hypothesis stem from the assumption
that the presence of A3G into virions is sufﬁcient and necessary to
inﬂuence its antiviral activity. Therefore, to examine if A3G variants
were active against HIV-1Δvif viruses, we tested all our isogenic
proteins for their ability to inhibit viral infectivity (Fig. 5A). As
expected, A3G proteins bearing N-terminal stabilizing amino acids
(Met and Gly) inhibited HIV-1Δvif infection comparably to A3G WT
(Fig. 5A). Surprisingly, A3G proteins bearing secondary (Asp) and
tertiary (Asn) amino-terminal residues also exhibited antiviral
activities similar to A3G WT (Fig. 5A). Initially, we expected a
reduction in the antiviral activity of these A3G variants, since Asn-A3G
and Asp-A3G are considered destabilizing residues with lower half-
lives. Nonetheless, the total amount of Asn-A3G and Asp-A3G in the
cell at 85 and 65 min, respectively, was sufﬁcient to be incorporated
into virions and inhibit HIV-1Δvif infection to a level similar to wild-
type protein (Fig. 5A). In contrast, the ability of Arg-A3G and Phe-A3G
to inhibit HIV-1Δvif infectivity was greatly impaired when compared
to the more stable proteins (Fig. 5A). As expected, Leu-A3G (t1/
2=5 min) did not display any antiviral effect in the absence of Vif
(Fig. 5A). Interestingly, similar incorporation levels of A3G proteins
displaying different half-lives (Asp-A3G and Arg-A3G) (Fig. 5C, lanes 5
and 6) did not result in a similar inhibition of HIV-1Δvif infection
(Fig. 5A). When we determined the infectivity of wild-type viruses
(Fig. 5B), the variations observed among the virions produced in the
presence of the different A3G proteins, were not signiﬁcant (pN0.05).
Finally, we decided to dilute wild-type A3G to levels comparable to
those observed with Phe-A3G, and compare the ability to inhibit HIV-
1Δvif infection. As seen in Fig. 5E (lower panel), when we reduced by
10-fold the amount of A3G WT transfected, we obtained a level of
expression comparable to Phe-A3G (Fig. 5E, compare lanes 1 and 8).
Interestingly, when we compared the ability of A3G WT and Phe-
A3G to inhibit HIV-1Δvif infection, we showed that similar expression
levels of these proteins did not result in a similar reduction of viral
infectivity (Fig. 5E, upper panel). In fact, the ability of A3GWT to inhi-
bit HIV-1Δvif infection was more than 2-fold higher than that of Phe-
A3G, regardless of a similar expression. These results suggest that
differences of the different constructs to inhibit viral infection were
the result of the half-life of each protein, and not an artefact caused by
differences in protein expression. Nevertheless, since deamination
assays for each X-A3G construct were only performed qualitatively,
one cannot exclude that alterations in activity of X-A3G can inﬂuence
viral infectivity. Therefore, caution should be taken in consideration
when interpreting these results.
Furthermore, real-time PCR analysis detected the presence of A3G
mRNA transcripts in equal amounts in all the samples used for the
production of HIV-1Δvif viral stocks. This result conﬁrmed that the
differences observed in A3G expression (Fig. 5C) were not caused bydifferences in A3G transcription efﬁciency (Fig. 6), but instead were
the result of the half-life of each protein.
Discussion
In this work we investigated the relationship between A3G half-
life and its antiviral activity. Assessing the time required for A3G
incorporation into virions is important for determining how promptly
Vif must act to induce its degradation and how long A3Gmust exist in
the cytoplasm to be recruited to viral particles. To achieve this goal,
we employed an ubiquitin-fusion strategy which allowed us to
express A3G proteins with different half-lives that differed frommore
than 4 h (Met-A3G and Gly-A3G) to less than 5 min (Leu-A3G). In
addition, this strategy can assess both the time required for A3G
incorporation into virions and its antiviral activity. Consequently, it is
possible to maintain A3G with a similar half-life in the cell and
evaluate its phenotype.
It has been previously shown that the intracellular half-life of A3G
WT can be reduced from the original 8 h to 1–2 min when expressed
in the presence of Vif (Marin et al., 2003). By using this strategy, we
obtained an efﬁcient control of A3G intracellular concentration to a
level similar to that observed in the presence of the viral protein. Thus,
we determined that by changing the ﬁrst amino acid residue of A3G
we were able to destabilize A3G and mimic the effect of Vif on A3G
steady-state, which permits monitoring the antiviral activity of A3G in
a Vif-free environment.
Ours results showed that A3G incorporation into virions occurs
shortly after its synthesis (t1/2=13 min) (Fig. 5C, lane 7) and the
quantity of incorporated protein increases from 13 to 85min (Figs. 5C,
D). Interestingly, after 85 min the quantity of protein present into
virions remains similar for the different constructs (Figs. 5C, D). This
observation is in accordance with a previous work, showing the pre-
ferential recruitment of A3G into HIV-1 virions within 1.5 h after its
synthesis (Soros et al. 2007).
When the antiviral properties of A3G variants were assayed, we
observed a lack of correlation between the amount protein present
into virions and their antiviral activity. Incorporation of Arg-A3G (t1/
2=28 min) into virions was signiﬁcantly higher than Phe-A3G (t1/
2=13 min) (pb0.05), but an increase in the antiviral effect was not
observed (pN0.05). Furthermore, when similar comparison is made
between Arg-A3G (t1/2=28 min) and Asp-A3G (t1/2=65 min),
the quantity of protein into virions is similar but inhibition of HIV
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According to these results, there is a time lapse between A3G incor-
poration into virions and its ability to inhibit HIV infection. We may
conclude that the presence of A3G into virions is not sufﬁcient to
inhibit HIV infection.
It has been proposed that incorporation of A3G into virions
involves both viral and nonviral RNAs (Svarovskaia et al., 2004, Khan
et al., 2007). While there is increasing evidence that binding to RNA is
important for A3G incorporation into viral particles, we show here
that A3G can be incorporated into virions without having an antiviral
effect on HIV-1 infection (Fig. 5). Furthermore, there is an increasing
concern that the discrepant results on the role of RNA in A3G packa-
ging could be due to relative differences in protein expression (Strebel
and Khan, 2008). In our study, however, we were able to control the
intracellular concentration of A3G by manipulating its intracellular
half-life. We showed that antiviral activity is only achieved for those
A3G variants with a half-life longer than 65 min. It is possible that
A3G antiviral effect may also be dependent on the encapsidation of
cellular or viral RNAs that are not readily available at earlier stages
(t1/2=13 min and t1/2=28 min). Although this is a tantalizing
hypothesis due to our Phe-A3G results compared with A3G wt, the
deaminase activity of each protein was only determined qualitatively
(Supplementary data). Hence, we cannot exclude the possibility that
differences in Phe-A3G and A3G wt deaminase activity may be
important in viral infectivity. Moreover, deaminase-independent
antiviral activities were not assessed in this report. Therefore, one
cannot rule out this variable as a possible source for differences in
antiviral activity seen in our assays. More studies need to be con-
ducted to evaluate if proposed endogenous helper factors of A3G can
also be incorporated into virions at later stages of viral assembly (Han
et al., 2008).
It has been shown that fusion of UBA2 to A3G could potentially be
used to antagonize Vif-mediated degradation of A3G by preventing
polyubiquitination (Li et al., 2008). These authors wisely decided to
stabilize A3G reaching a stronger inhibitory effect on HIV-1 infectivity
(Li et al., 2008). However, care must be taken when attempting to
upregulate A3G expression as A3G mRNA is highly expressed in some
tumor cells (Jarmuz et al., 2002). Therefore, based on our results, we
suggest that destabilization of A3G to a level where it can still inhibit
HIV infection similar to wild-type protein without any deleterious
effect on the cell physiology would be a better approach.
Materials and methods
Plasmids and DNA constructs
The full-length molecular clone of HIV-1 (pNL4.3) was obtained
from the NIH AIDS Research and Reference Reagent Program (Cat. #
114), andwas used for the production of infectious virus. Vif-defective
molecular clone pNL4.3Δvif (Karczewski and Strebel, 1996) was used
for the production of Vif-defective HIV-1 virus. pcDNA3.1-APOBEC3G-
HA (A3G) was used for the expression of C-terminally epitope-tagged
human A3G proteins and was kindly supplied by Dr. Klaus Strebel.
pcDNA-Vif was obtained from the NIH AIDS Research and Reference
Reagent Program (Kao et al., 2003). pEGFP⁎IRES-Ub-X (Mulder and
Muesing, 2000) vector was kindly supplied by Dr. Muesing and was
used for the subsequent cloning steps. For the insertion of A3G
downstream of the pEGFP⁎IRES-Ub-X sequence, A3G was ampliﬁed
by PCR using oligos: 5′-GAG GAG GAG GCG GGG CCC AGG CGG CCA
TGA AGC CTC ACT TCA GAA CAC AGT G-3′ and 5′-GAG GAG GAG GAG
GAG GAG CCT GGC CGG CCT GGC CGT TTT CCT GAT TCT GGA GAA TGG
C-3′, containing the restriction site for SﬁI and ligated to the cloning
vector linearized by restriction digestion with SﬁI. The resultant
ligation originated a bicistronic A3G expression vector, where trans-
cription of the mRNA is initiated at the cytomegalovirus promoter/
enhancer upstream of the EGFP coding sequence, along with aninternal ribosome entry site (IRES) upstream of the Ub-X-A3G gene
segment. Seven different amino acid sequences coding for, Met, Gly,
Asn, Asp, Arg, Phe, and Leu, were introduced downstream of the Ub
sequence by site directed mutagenesis using the Quick Change™ Site-
directed Mutagenesis Kit (Stratagene) as described by the manufac-
turer. All constructs were subjected to sequence analysis for detection
of undesirable mutations.
Cell culture and transfections
Human embryonic kidney (HEK) 293T and P4 cell lines (HeLa-CD4
LTR-LacZ) were obtained from the NIH AIDS Research and Reference
Reagent Program Catalog and grown in Dulbecco's modiﬁed Eagle's
medium (DMEM) containing 10% foetal calf serum, 1× penicillin–
streptomycin–fungizone mixture and L-Glutamine (Bio Whittaker).
For transfections, 293T cells were grown in 6-well or 60-mm plates to
nearly 70% conﬂuent, as appropriate. Cells were transfected using the
calcium phosphate precipitation method. A total of 1 to 10 μg of
plasmid DNA was used for transfections in 6-well or 60-mm plates,
unless stated. To generate VSV-G-pseudotyped virions, 293T cells
were cotransfected with a plasmid expressing the VSV-G envelope.
Total amounts of transfected DNA were kept constant in all trans-
fections by adding empty-vector DNA (pcDNA 3.1) (Invitrogen), when
appropriate. Cells were harvested typically 40–44 h post-transfection.
Proteasome inhibitor MG-132 (10 mM in DMSO) was purchased from
Calbiochem (Cat. # 474790). Cycloheximide was purchased from
Aldrich (cat. C1988-1G) and stock solution was prepared in DMSO.
Cell Proliferation Reagent WST-1 was purchased from ROCHE (Cat. #
11644807001).
Virus production and infectivity assays
Virus stocks were prepared by transfection of 293T cells with
pNL4.3 or pNL4.3Δvif in the presence of wild-type A3G-HA or pEGFP-
IRES-Ub-X-APOBEC3GHA, as appropriate. Virus-containing super-
natants were harvested 40 to 44 h after transfection. Centrifugation
removed cellular debris (3 min, 3000 ×g), and non-concentrated
clariﬁed supernatants were used for infectivity assays in P4 cells. For
immunoblot analysis of viral proteins, virus-containing supernatants
(2 ml) were concentrated by ultracentrifugation through 1 ml of 20%
sucrose in phosphate-buffered saline (PBS) as described previously
(Kao et al., 2003).
To determine viral infectivity, viral stocks were normalized for
equal p24 concentration, detected using the AIDS Vaccine Program
HIV-1 p24CA Antigen Capture Assay Kit, and used to infect 1.5×104
HeLa P4 cells in a 96-well plate in a total volume of 200 μl. HeLa P4
cells contain β-galactosidase indicator gene under the control of
pNL4.3 long terminal repeat. Quantiﬁcation of the β-galactosidase
activity was performed in cell lysates forty-eight hours after infection,
using a colorimetric assay based on the cleavage of chlorophenolred-
β-D-galactopyranoside (CPRG) by β-galactosidase (Roche) (Eustice
et al., 1991). Brieﬂy, P4 cells were placed in 100 μl of lysis buffer
(MgCl2 5 mM, NP40 0.1% in phosphate-buffered saline) and after
30min on ice cell lysates were incubatedwith 100 μl of reaction buffer
(CPRG 6 mM in lysis buffer) between 5 min and 2 h at 37 °C.
Antisera
For detection of APOBEC3G HA-tagged, an anti-HA HRP mono-
clonal antibody (Roche) was used. Detection of EGFP protein was
performed with anti-EGFPmouse monoclonal antibody (Roche). The
HIV-1 capsid p24 protein was detected using the anti-p24 anti-
mouse supplied by the NIH AIDS Research and Reference Reagent
Program (Cat. # 530). GAPDH was used as a loading control and
the antibody used was purchased from Santa-Cruz Biotechnology
(GAPDH 6C5).
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For detection of intracellular proteins, whole-cell-lysates were
prepared as follows. Transfected 293T cells were washed once with
warm phosphate-buffered saline (PBS) and re-suspended in RIPA
supplementedwith 0.1% of Triton X-100 and protease inhibitor cocktail
EDTA-free (Roche) (500 μl/106 cells). Cell lysates were mixed with
equal volume of sample buffer (4% sodium dodecyl sulfate [SDS],
125 mM Tris–HCl [pH 6.8], 10% 2-mercaptoethanol, 10% glycerol, and
0.02% bromophenol blue). Proteins were solubilized by boiling for
10 min at 95 °C. Proteins were separated by 12% SDS-PAGE (National
Diagnostics), transferred to nylon membranes (Hybond, Amersham)
and reacted with appropriate antibodies as described in the text.
Membranes were then incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies (Amersham Biosciences) and visual-
ized by enhanced chemiluminescence (ECL) (Amersham Biosciences).
Total RNA extraction and qRT-PCR
Total RNA was extracted from transfected 293T cells using Trizol
reagent (Invitrogen) following manufacturer's instructions. cDNA
products were synthesized from RNA isolated from 2×106 cells, using
random hexamers and Superscript II RNA polymerase (Invitrogen).
A3G mRNA levels were quantiﬁed using SYBR Green (Invitrogen)
according to the manufacturer's instructions. The primers used for the
ampliﬁcation of the different A3G constructs were as follows: A3G
forward primer: 5′-GGC TCC ACA TAA ACA CGG TTT C-3′ (nucleotides
735 to 756); A3G reverse primer: 5′-AAG GGA ATC ACG TCC AGG AA-
3′ (nucleotides 803 to 784). Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH)was used as a normalizing control with the following
primers: forward, 5′-GGT GGT CTC CTC TGA CTT CAA CA-3′; reverse,
5′-GTT GCT GTA GCC AAA TTC GTT GT-3′. Each SYBR Green reaction
contained 12.5 μl 2× SYBR Green PCR mix (Invitrogen), 0.25 μl of each
10 μM primer, and 1 μl of 1:4-diluted cDNA products. Absolute mRNA
copy numbers were calculated by generating standard curves
generated by serial dilutions of a plasmid containing the APOBEC3G
gene and the cDNA product (GAPDH). Each sample was run in
triplicate in an ABI 7000 (Applied Biosystems) with one cycle at 50 °C
(2 min) followed by 95 °C (10 min) and 40 at 95 °C (15 s) followed by
60 °C (1 min) (Cho et al., 2006).
Degradation rate quantitation
For quantiﬁcation of the degradation rate of each Ub-X-A3GHA
mutants, 293T cells were transfected in a 60 mm plate with 10 μg of
plasmid DNA encoding the different A3G mutants. 16–20 h after
transfection, cells were split in 6-well plates and treated next day were
with 100 μg/ml of cycloheximide for 0, 1, 2, 3, and 4 h for A3GWT, Ub-
Met-A3G, andUb-Gly-A3G transfections; 0, 1, 2, and 3h for Ub-Asn-A3G
and Ub-Asp-A3G transfections; 0, 20, 40, and 60 min for Ub-Arg-A3G
transfection, and 0, 5, 10, and 20 min for Ub-Leu-A3G transfection. For
each sample, cellular lysates were obtained and protein content ana-
lyzed by Western blot using appropriate antibodies (as described
above). Quantiﬁcation of band density was performed using Quantity
One 4.6.3 software (Bio-Rad Laboratories, USA).
Determination of A3G deaminase activity
A3G deaminase activity was determined in an in vitro quantitative
assay as described by Nowarski et al. (2008). This is based on PCR
ampliﬁcation of a synthetic ss-deoxyoligonucleotide harboring the 5′
CCCA 3′ target sequence for A3G deamination as substrate. A3G WT
and Ub-X-A3G mutants were expressed in 293T cells following trans-
fection with 10 μg of plasmid DNA, as previously described. Immuno-
precipitation and puriﬁcation of HA-tagged A3G proteins were
performed by incubation of crude lysates with anti-HA High AfﬁnityMatrix (Roche), according to the manufacturer's instructions. Puriﬁed
A3G proteins were treated with DNAse I (Invitrogen) before
incubation with a deamination substrate according to the manufac-
turer's instructions. Puriﬁed protein (40 fmol/μl) was incubated with
a ss-deoxyoligonucleotide substrate (10 fmol/μl) in the presence of
40 μM RNAse A, 25 mM Tris buffer and 0.1 mg/ml BSA for 30 min at
37 °C. After incubation, resultant products of deamination reaction
were ampliﬁed by PCR and subsequently digested with Eco147I.
Brieﬂy, one round of PCR was performed at 94 °C (3 min) followed by
ﬁfteen rounds at 94 °C (30 s) and 61 °C (30 s). Restriction-reaction
products were loaded onto 14% gels and separated by PAGE. Gels were
stained with SYBR gold nucleic acid stain (Molecular Probes) diluted
1:10,000 in 0.5 Tris-Borate-EDTA buffer (TBE, pH 7.8), visualized by
UV light (312 nm). Optical density scans was performed using
Quantity One 4.6.3 software (Bio-Rad Laboratories, USA).
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